1-4 of 4
Lars Möllgård, MD, Phd
Close
Sort by
Journal Articles

Poor Outcome in Secondary Acute Myeloid Leukemia (AML): A First Report From the Population-Based Swedish Acute Leukemia Registry

Soren Lehmann, MD, PhD, Vladimir Lazarevic, MD, Ann-Sofi Hörstedt, Erik Hulegårdh, MD, Christer Nilsson, MD, Petar Antunovic, MD, Åsa Rangert Derolf, MD, PhD, Lars Möllgård, MD, PhD, Bertil Uggla, MD, PhD, Lovisa Vennström, MD, Anders Wahlin, MD, PhD, Martin Hoglund, MD, PhD, Dick Stockelberg, MD, PhD, Gunnar Juliusson, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 130.
https://doi.org/10.1182/blood.V120.21.130.130
Published: 2012
Journal Articles

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Magnus Tobiasson, MD, Lena Brandefors, MD, Ingunn Dybedal, MD, PhD, Hege Garelius, MD, Michael Grövdal, MD, PhD, Inge Hoegh Dufva, MD, PhD, Lars Kjeldsen, MD, PhD, Lars Nilsson, MD, PhD, Astrid Olsnes Kittang, MD, PhD, Anna Porwit, MD, PhD, Leonie Saft, MD, Mette Skov Holm, MD, PhD, Lars Möllgård, MD, Phd, Eva Hellström-Lindberg
Journal: Blood
Blood (2011) 118 (21): 3798.
https://doi.org/10.1182/blood.V118.21.3798.3798
Published: 2011
Journal Articles

RITA Activates p53 Function in Chronic Lymphocytic Leukaemia Cells and Induces Apoptosis.

Hareth Nahi, MD, Mats Merup, MD/PhD, Lars Möllgård, MD/PhD, Galina Selivanova, Christer Paul
Journal: Blood
Blood (2005) 106 (11): 5536.
https://doi.org/10.1182/blood.V106.11.5536.5536
Published: 2005
Journal Articles

Effects of the FLT3 Inhibitor PKC 412 in Combination with Cytostatic Drugs In Vitro in Acute Myeloid Leukemia.

Lars Möllgård, MD PhD, Sofia Bengtzen, Thoas Fioretos, Anna Andersson, Christer Paul, Sören Lehmann, MD PhD
Journal: Blood
Blood (2004) 104 (11): 1810.
https://doi.org/10.1182/blood.V104.11.1810.1810
Published: 2004